Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.59 |
| ▸ | CNR2 | P34972 | 15/20 | 0.55 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | QDPR | P09417 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300623 | 0.82 | HTR2C (0.67) | HTR2CSLC18A3SIGMAR1QDPR | |
| Hydrochloric Acid SCHEMBL23858205 | 0.80 | HTR2C (0.68) | HTR2CSLC18A3SIGMAR1QDPR | |
| SCHEMBL8047163 | 0.79 | HTR2C (0.73) | HTR2CSLC18A3SIGMAR1QDPR | |
| SCHEMBL30228302 | 0.79 | HTR2C (0.62) | HTR2CSLC18A3SIGMAR1QDPR | |
| SCHEMBL15317742 | 0.76 | HTR2C (0.59) | HTR2CCNR2SLC18A3SIGMAR1QDPR | |
| SCHEMBL19731506 | 0.74 | HTR2C (0.46) | HTR2CCNR2SLC18A3SIGMAR1 | |
| SCHEMBL373310 | 0.74 | HTR2C (1.00) | HTR2CSLC18A3SIGMAR1QDPR | |
| Enefexine SCHEMBL499360 | 0.74 | SLC18A3 (0.55) | HTR2CSLC18A3SIGMAR1QDPR | |
| SCHEMBL14684852 | 0.74 | HTR2C (0.51) | HTR2CSLC18A3SIGMAR1QDPR | |
| SCHEMBL22692974 | 0.73 | CNR2 (0.49) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | HTR2C 3493/4885CNR2 2766/4885SLC18A3 2543/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | HTR2C 3493/4885CNR2 2766/4885SLC18A3 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.